Redox unbalance: NADPH oxidase as therapeutic target in blood pressure control

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 5, 2010, Pages

  Rabêlo, Luiza A ^a,b   De Souza, Valéria Nunes ^a   Fonseca, Lucas José Sá Da ^a   Sampaio, Walkyria O ^b,c  

^a FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c CENTRO UNIVERSITÁRIO DE BELO HORIZONTE   (Brazil)

Author keywords

Cardiovascular diseases; NADPH oxidase; NADPH oxidase inhibitors; Oxidation reduction; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; APOCYNIN; ARGININE; ASCORBIC ACID; BIOPTERIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENYLIODONIUM SALT; NITRIC OXIDE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; OXYGEN; PR 39; PROTEIN P47PHOX; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; UNCLASSIFIED DRUG; VITAMIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIET THERAPY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MACROPHAGE; NEUTROPHIL; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASODILATATION; VITAMIN SUPPLEMENTATION;

BLOOD PRESSURE; HUMANS; HYPERTENSION; NADPH OXIDASE; OXIDATION-REDUCTION;

EID: 77953735811     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003; 24: 471-8. (Pubitemid 37088172)
2. Cangemi R, Angelico F, Loffredo L, Ben MD, Pignatelli P, Martini A, et al. Oxidative stress-mediated arterial dysfunction in patients with metabolic syndrome: effect of ascorbic acid. Free Radic Biol Med. 2007; 43: 853-9. (Pubitemid 47102131)
3. Cosentino F, Barker J, Brand MP, Heales SJ, Werner ER, Tippins JR, et al. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 496-502. (Pubitemid 32323379)
4. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolopoprotein e deficient mice. Circulation. 2008; 117: 2377-87. (Pubitemid 351653554)
5. Dusting GJ, Selemidis S, Jiang F. Mechanisms for suppressing NADPH oxidase in the vascular wall. Mem Inst Oswaldo Cruz. 2004; 100 (Suppl.I): 97-103. (Pubitemid 40685446)
6. Heumüller S, Wild S, Barbosa-Sicard E, Schmidt HHHW, Busse R, Schröder K, et al. Apocynin is not an inhibitor of vascular reduced nicotinamide-adenine dinucleotide phosphate oxidases but an antioxidant. Hypertension. 2008; 51: 1-7.
7. Lassègue B, Clempus RE. Vascular NAD(P)H oxidase: specific features, expression, and regulation. Am J Physiol Regul Comp Physiol. 2003; 285: R277-R297.
8. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008; 117: 2626-36.
9. Molnar J, Yu S, Mzhavia N, Pau C, Chereshnev I, Dansky HM. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ Res. 2005; 96; 1178-84. (Pubitemid 40827693)
10. Paravicini TM, Touyz RM. NADPH oxidase, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008; 31: S170-S180.
11. Rajagopalan S, Kutrz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1999; 97: 1916-23.
12. Sampaio WO, Castro CH, Santos RAS, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007; 50: 1093-8.
13. Schiffrin EL, Touyz RM. Inflammation and vascular hypertrophy induced by angiotensin II: role of NADPH oxidase-derived reactive oxygen species independently of blood pressure elevation? Arterioscler Thromb Vasc Biol. 2003; 23: 707-9.
14. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003; 42: 1075-81.
15. Touyz RM, Yao G, Schiffrin EL. c-Src Induces phosphorylation and translocation of p47phox: role of superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003; 23: 1-9.
16. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002; 90: 1205-13.
17. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension. 2005; 45: 530-7.
18. Touyz RM, Schiffrin EL. Reactive oxygen species and hypertension: a complex association. Antioxid Redox Signal. 2008; 10: 1041-4.
19. Ülker S, McMaster D, McKeown PP, Bayraktutan U. Antioxidante vitamins C and E ameliorate hyperglycaemia-induced oxidative stress in coronary endothelial cells. Diabetes, Obes Metab. 2004; 6: 442-51.
20. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci STKE. 2006; 349: re8.
21. Yokoyama M, Inoue N. How vascular NAD(P)H oxidase activity and nox isoform expression are regulated. Arterioscler Thromb Vasc Biol. 2004; 24: 1540-1. (Pubitemid 39180874)
22. Paravicini TM, Gulluyan LM, Dusting GJ, Drummond GR. Increased NADPH oxidase activity, gp91phox expression, and endothelium-dependent vasorelaxation during neointima formation in rabbits. Circ Res. 2002; 91: 54-61.
23. Baehner RL, Gilman N, Karnovsky ML. Respiration and glucose oxidation in human and guinea pig leukocytes comparative studies. J Clin Invest. 1970; 49: 692-700.
24. Soberman RJ. The expanding network of redox signaling: new observations, complexities, and perspectives. J Clin Invest. 2003; 111: 571-4.
25. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004; 44: 248-52.
26. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, Chantemele EB, et al. Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol. 2008; 28: 1627-33.
27. Zhang L, Sheppard OR, Shah AM, Brewer AC. Positive regulation of the NADPH oxidase NOX4 promoter in vascular smooth muscles cells by E2F. Free Radic Biol Med. 2008; 45 (5): 679-85.
28. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373-6.
29. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and disfunction: testing and clinical relevance. Circulation. 2007; 115: 1285-95.
30. Evora PRB, Pearson PJ, Rodrigues AJ, Viaro F, Schaff HV. Relaxamento dependente do endotélio causado pela poli-L-arginina: implicações sobre a hiperpolarização como mecanismo de vasodilatação. Arq Bras Cardiol. 2003; 80: 621-5.
31. Pereira LMM, Mandarim-de-Lacerda CA. Estudo quantitativo da microcirculação miocárdica na hipertensão arterial por progressiva inibição da síntese do óxido nítrico. Arq Bras Cardiol. 1999; 73: 407-12.
32. Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M, et al. Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res. 2007; 101: 692-702.
33. Fitzgerald SM, Kemp-Harper BK, Parkington HC, Head GA, Evans RG. Endothelial dysfunction and arterial pressure regulation during early diabetes in mice: roles for nitric oxide and endothelium-derived hyperpolarization factor. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R707-R713.
34. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007; 34: 906-11.
35. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hasfner G, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003; 349: 1605-13.
36. de Haan JB, Witting PK, Stefanovic N, Pete J, Daskalakis M, Kola I, et al. Lack of the antioxidant glutathione peroxidase-1 does not increase atherosclerosis in C57BL/J6 mice fed a high-fat diet. J Lipid Res. 2006; 47: 1157-67.
37. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 2004; 122: 339-52.
38. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schöneich C, et al. S-glutathiolation by peroxinitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med. 2004; 10: 1200-7. (Pubitemid 39540436)
39. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K, et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation. 2008; 117: 2211-23.
40. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in ApoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001; 103: 1282-8. (Pubitemid 32221353)
41. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. J Clin Invest. 2001; 107: 23-4.
42. Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, et al. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension. 2007; 51: 127-33. (Pubitemid 350307114)
43. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev. 1994; 74: 139-62.
44. Yu Z, Zhang J, Wang X, Chen J. Excessive copper induces the production of reactive oxygen species, which is mediated by phospholipase D, nicotinamide adenine dinucleotide phosphate oxidase and antioxidant system. J Integr Plant Biol. 2008; 50 (2): 157-67.
45. Wiggers GA, Peçanha FM, Briones AM, Perez-Girón JV, Miguel M, Vassallo DV, et al. Low-mercury concentrations cause oxidative stress and endothelial dysfunction in conductance and resistance arteries. Am J Physiol Heart Circ Physiol. 2008; 295: H1033-H1043.
46. Wassmann S, Wassman K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 2004; 44: 381-6. (Pubitemid 39281479)
47. Ülker S, McKeown PP, Bayraktutan U. Vitamins reverse endothelial dysfunction through regulation of eNOS And NADPH oxidase activities. Hypertension. 2003; 41: 534-9.
48. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007; 87: 315-424. (Pubitemid 46217686)
49. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant Effects of Vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001; 38 [part2]: 606-11.
50. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000; 87: 26-32.
51. Hildeman DA, Mitchell T, Kappler T, Marrack P. T cell apoptosis and reactive oxygen species. J Clin Invest. 2003; 111: 575-81. (Pubitemid 36278573)
52. Fresquet F, Pourageaud F, Leblais V, Brandes RP, Savineau JP, Marthan R, et al. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arteries induced by chronic hypoxia. Br J Pharmacol. 2006; 148: 714-23. (Pubitemid 43996780)
53. Xu P, Costa-Gonçalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, et al. Endothelial dysfunction and elevated blood pressure in mas genedeleted mice. Hypertension. 2008; 51 [part2]: 574-80.
54. Jankowski A, Grinstein S. A noinvasive fluorimetric procedure for measurement of membrane potential: quantification of the NADPH oxidase-induced despolarization in activated neutrophils. J Biol Chem. 1999; 274: 26098-104.
55. Cifuentes ME, Pagano PJ. c-Src and smooth muscle NAD(P)H oxidase: assembling a path to hypertrophy. Arterioscler Thromb Vasc Biol. 2003; 23: 919-21.
56. Chen K, Kirber MT, Xiao H, Yang Y, Keaney JF Jr. Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol. 2008; 181: 1129-39.
57. Schäppi MG, Jaquet V, Belli DC, Krause K. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol. 2008; 30: 255-71.
58. Rueckschloss U, Galle J, Holtz J, Zerkowski H, Morawietz H. Induction of NAD(P)H Oxidase by oxidized low-density lipoprotein in human hendothelial cells: antioxidative potencial of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy. Circulation. 2001;104:1767-72.
59. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest. 2003; 111: 769-78. (Pubitemid 37074948)
60. Touyz RM, Chen X, Tabet F, Yao G, He H, Quinn MT, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res. 2002; 90: 1205-13.
61. Ambasta RK, Schreiber JG, Janiszewski M, Busse R, Brandes RP. Noxa1 is a central component of the smooth muscle NADPH oxidase in mice. Free Radic Biol Med. 2006; 41 (2): 193-201.
62. Lassègue B, Sorescu D, Szöes K, Yin Q, Akers M, Zhang Y, et al. Novel gp91phox homologues in vascular smooth muscle cells: nox 1 mediates angiotensin-II-induced superoxide formation and redox-sensitive signaling pathways. Cir Res. 2001; 88: 888-94.
63. Petry A, Djordjevic T, Weitnauer M, Kietzmann T, Hess J, Gorlach A. Nox2 and Nox4 mediate proliferative response in endothelial cells. Antioxid Redox Signal. 2006; 8 (9-10): 1473-84.
64. Kahles T, Luedike P, Endres M, Galla HJ, Steinmetz H, Busse R, et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke. 2007; 38: 3000-6.
65. Steinbretcher UP. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem. 1987; 262: 3603-8.
66. Griendling KK, Minuri CA, Ollerenshaw TD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth cells. Circ Res. 1994; 74: 1141-8.
67. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000; 52 (4): 639-72.
68. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassegue B, Griendling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxid Redox Signal. 1999; 1 (2): 167-79.
69. Janiszewiski M, Lopes LR, Carmo AO, Pedro MA, Brandes RP, Santos CX, et al. Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells. J Biol Chem. 2005; 280 (49): 40813-9.
70. Kyam M, Yoshizumi M, Tsuchiya K, Kagami S, Izawa Y, Fujita Y, et al. Src and Cas are essentially but differentially involved in angiotensin II-stimulated migration of vascular smooth muscle cells via extracellular signa-regulated kinase 1/2 and c-jun NH2-terminal kinase activation. Mol Pharmacol. 2004; 65: 832-41.
71. Gual JL. Role of focal adhesion kinase in integrin signaling. Int J Bioch Cell Biol. 1997; 29: 1085-96.
72. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005; 45: 773-9.
73. Kawahara T, Quinn MT, Lamberth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Doux) family of enzymes. BMC Evol Biol. 2007; 7: 109.
74. Rabêlo LA, Cortes SF, Alvarez-Leite J, Lemos VS. Endothelium dysfunction in LDL receptor knockout mice: a role for H2O2. Br J Pharmacol. 2003; 138: 1215-20.
75. Thengchaisri N, Shipley R, Ren Y, Parker J, Kuo L. Exercise training restores coronary arteriolar dilation to NOS activation distal to coronary artery occlusion: role of hydrogen peroxide. Arterioscler Thromb Vasc Biol. 2007; 27: 791-8.
76. Marnet LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and eletrophiles and their reaction with DNA and protein. J Clin Invest. 2003; 111: 583-93.
77. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension. 2002; 40: 774-9.
78. Tarpey MM, White CR, Suarez E, Richardson G, Radi R, Freeman BA. Chemiluminescent detection of oxidants in vascular tissue: lucigenin but not coeleterazine enhances superoxide formation. Circ Res. 1999; 84: 1203-11.
79. Stocker R, Huang A, Jeranian E, Hou JY, Wu TT, Thomas SR, et al. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism. Arterioscler Thromb Vasc Biol. 2004; 24: 2028-33.
80. Klein JA, Ackerman SL. Oxidative stress, cell cycle and neurodegeneration. J Clin Invest. 2003; 111: 785-93.
81. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997; 99: 41-6.
82. Bahia L, Aguiar LGK, Villela NR, Bottino D, Bouskela E. O endotélio na síndrome metabólica. Arq Bras Endocrinol Metab. 2006; 50 (2): 291-303.
83. Touyz RM. Vascular remodeling, retinal arteries, and hypertension. Hypertension. 2007; 50: 603-4.
84. El-Benna J, Dang PM, Gougerot-Pocidalo M. Priming of neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008; 30: 279-89.
85. Paul R, Obermaier B, Van Ziffle J, Angele B, Pfister HW, Lowell CA, et al. Myeloid Src kinases regulate phagocytosis and oxidative burst in pneumococcal meningites by activating NADPH oxidase. J Leukoc Biol. 2008; 84 (4): 1141-50.
86. Delwing D, Delwing D, Bavaresco CS, Wyse ATS. Protective effect of nitric oxide synthase inhibition or antioxidants on brain oxidative damage caused by intracerebroventricular arginine administration. Brain Res. 2008; 1193: 120-7.
87. Li B, Guo Y, Sun M, Dong H, Wu S, Wu D, et al. The NADPH oxidase is involved in lipopolysaccharide-mediated motor neuron injury. Brain Res. 2008; 1226: 199-208.
88. Touyz RM. Apocynin, NADPH oxidase and vascular cells: a complex matter. Hypertension. 2008; 51: 172-4.
89. Godbole AS, Lu X, Guo X, Kassab GS. NADPH oxidase has a directional response to shear stress. Am J Physiol Heart Circ Physiol. 2009; 296: H152-H158.
90. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensina II. Proc Natl Acad Sci USA. 1997; 94: 14483-8.